Insider buying last 90 days
No open-market insider purchases were filed for HNGE in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Hinge Health moves higher this week on the back of third-quarter results reported 2 November, with revenue growth of 52% year over year and an earnings beat against estimate, alongside a raised full-year outlook. The earnings call cited higher member engagement, client additions, and improved operating leverage, with gross margin reaching 88% and operating income hitting $77M at a 33% margin. A note on rising earnings estimate revisions also points to continued near-term interest in the shares.
The stock closes at $122.19, up 5.6%, sitting above both its 50-day average of $101.53 and its 200-day average of $69.32, with the shorter average above the longer one, consistent with an established uptrend. The GekkoIndex reads 46.8, placing HNGE in the Neutral zone, while the price sits 7.9% above the Gekko Fair Value of $113.2.
The next earnings date falls on 9 February 2027, 91 days out, placing it beyond a typical 20-trading-day holding window. No insider, Congress, or unusual options activity shows up in the current windows, leaving smart-money signals quiet for now. Analyst coverage remains heavily tilted toward buy ratings among 11 firms, with a consensus target implying further upside from current levels. The gap to Gekko Fair Value, along with the historically wide average reaction of 12.4% around past reports, bears watching.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Hinge Health scores 2 supportive, 2 mixed and 0 headwinds across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed0 headwinds
Above 50 and 200-day
Close $115.39 is above the 50-day ($103.85) and 200-day ($70.95) averages, and the 50-day is above the 200-day.
See the chart53.5, Neutral
Reading 53.5 is in the Neutral zone.
See the GekkoIndex0.9% below
Price is within 5% of Gekko Fair Value (0.9% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 86 days
Next report Feb 9, 2027, 86 days away — outside a typical 20-trading-day hold.
See earningsNo data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
Hinge Health closed at $115.39 on Nov 13, 2026, +172.6% over the past year, inside a 52-week range of $30.08 to $126.40.
Use the left and right arrow keys to read daily values.
Put HNGE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Hinge Health builds software aimed at musculoskeletal and joint health, giving people tools to address everyday joint and muscle issues, sudden injuries, ongoing chronic pain, and recovery after surgery. It is best known for offering a single platform that follows a patient through this whole range of musculoskeletal needs rather than treating each issue separately.
Beyond the clinical side of its platform, Hinge Health also handles administrative and operational support tasks tied to delivering this care, rounding out the service it provides.
Hinge Health was founded in 2012 and is headquartered in San Francisco, California. Its shares are listed on the NYSE under the ticker HNGE.
Hinge Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.5, in the Neutral zone, up 5 points over five sessions.
Up 5 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 19 | +3.7% | +22.5% | ||
| Accumulation | 74 | +2.8% | +6.9% | ||
| Neutral (current zone) | 215 | +0.9% | +5.5% | ||
| Distribution | 51 | +4.3% | +13.4% | ||
| Selling | 4 | Too few readings yet | |||
Average HNGE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Hinge Health trades 0.9% below Gekko Fair Value of $116.46, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Hinge Health shares are worth, recalculated every trading day.
$116.46
Gekko Fair Value, Nov 14, 2026
0.9% below fair value · About fair value
At the end of Aug 2026 the price was 6.1% below the estimate.
No open-market insider purchases were filed for Hinge Health, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for HNGE in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in HNGE were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Hinge Health has been buying back its own shares.
From company filings.
2of the funds Gekko tracks hold HNGE.
Hinge Health reports on Feb 9, 2027, after the close (86 days away), and beat the EPS estimate in 7 of its last 7 reports.
Feb 9, 2027
Expected after the close, 86 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 2, 2026 | $0.71 est $0.58 | $235.0M est $224.8M | +2.2% |
| Aug 4, 2026 | $0.66 est $0.28 | $212.8M est $201.5M | +4.0% |
| May 5, 2026 | $0.45 est $0.40 | $182.3M est $172.2M | +12.2% |
| Feb 10, 2026 | $0.49 est $0.43 | $170.7M est $156.7M | +20.5% |
| Nov 4, 2025 | $0.34 est $0.24 | $154.2M est $156.8M | −9.8% |
| Aug 5, 2025 | $0.67 est $0.09 | $139.1M est $132.4M | +25.6% |
| May 5, 2025 | $0.21 est $0.09 | $123.8M est $125.4M | — |
| Mar 10, 2025 | $0.35 | $117.3M | — |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Hinge Health is $135.38, +17.3% from the last close, from 11 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 11 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 10 | Stifel Nicolaus | $135 | +17.0% |
| Nov 3 | Raymond James | $138 | +19.6% |
| Nov 3 | Morgan Stanley | $131 | +13.5% |
| Nov 3 | Stifel Nicolaus | $135 | +17.0% |
| Nov 3 | Canaccord Genuity | $134 | +16.1% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Hinge Health’s market cap is $9.38B, with a P/E ratio of 32.8 and revenue of $800.8M over the last twelve months.
Coverage of Hinge Health this week reads negative: 0 positive, 1 neutral and 2 negative headlines.
Hinge Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| MSFTMicrosoft | Neutral | 10.6% above |
| PLTRPalantir Technologies | Accumulation | 8.2% below |
| ORCLOracle | Neutral | 27.9% below |
| PANWPalo Alto Networks | Accumulation | 0.6% above |
| CRWDCrowdStrike | Accumulation | 0.9% above |
| CRMSalesforce | Accumulation | 12.1% below |
A peer links to its own page where one exists.
Hinge Health’s market cap is $9.38B at the Nov 13, 2026 close of $115.39, with 68.49M shares outstanding. The shares trade on a P/E ratio of 32.8.
The consensus analyst 12-month price target for Hinge Health is $135.38, +17.3% from the last close. Of the 11 firms that rated the stock in the last 90 days, 10 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Hinge Health is about fair value: the Nov 13, 2026 close of $115.39 is 0.9% below Gekko Fair Value of $116.46. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Hinge Health is expected to report on Feb 9, 2027, after the market closes (86 days away). Analysts expect earnings of $0.74 per share on revenue of $249.2M. Hinge Health beat the earnings estimate in 7 of its last 7 reports, moving 12.4% on average across the report.
Hinge Health’s 52-week high is $126.40 and its 52-week low is $30.08; it closed at $115.39 on Nov 13, 2026, +172.6% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 4 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.